Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ivabradine
Drug ID BADD_D01218
Description Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing serious adverse effects.
Indications and Usage Ivabradine's indication by the FDA is to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.
Marketing Status Prescription
ATC Code C01EB17
DrugBank ID DB09083
KEGG ID D07165
MeSH ID D000077550
PubChem ID 132999
TTD Drug ID D0S9QA
NDC Product Code 70518-3309; 55513-813; 65977-0116; 55513-800; 55513-810
Synonyms Ivabradine | 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one | S 16257 | S-16257 | S16257 | S 16257-2 | S 16257 2 | S 162572 | S-16257-2 | S162572 | S-16260-2 | S162602 | S 16260-2 | S 16260 2 | S 162602 | Corlanor
Chemical Information
Molecular Formula C27H36N2O5
CAS Registry Number 155974-00-8
SMILES CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual impairment06.02.06.0080.002931%Not Available
Vitreous floaters06.09.01.0050.000202%
Vomiting07.01.07.003--
Weight decreased13.15.01.0050.000505%
Weight increased13.15.01.006--
Peripheral swelling08.01.03.053; 02.05.04.0150.000303%Not Available
Haemodynamic instability24.03.02.0060.000505%Not Available
Lymphatic disorder01.09.01.003--Not Available
Electrocardiogram PR prolongation13.14.05.0120.000202%Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.01.01.0030.000105%Not Available
Connective tissue disorder15.06.01.006--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.0490.000303%Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.000707%Not Available
Unevaluable event08.01.03.0510.000910%Not Available
Sinus node dysfunction02.03.03.017--
Ejection fraction abnormal13.14.02.0180.000202%Not Available
The 5th Page    First    Pre   5    Total 5 Pages